| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1032800941 |
| P356 | DOI | 10.2165/11316000-000000000-00000 |
| P698 | PubMed publication ID | 20583848 |
| P2093 | author name string | David F Archer | |
| P2860 | cites work | Compliance with hormone replacement therapy at Songklanagarind Hospital | Q79327379 |
| A study on urogenital complaints of postmenopausal women aged 50 and over | Q81156307 | ||
| Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial | Q83924322 | ||
| Estrogen receptors and human disease | Q24645374 | ||
| Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society | Q24658109 | ||
| Molecular basis of agonism and antagonism in the oestrogen receptor | Q27746278 | ||
| The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen | Q27766417 | ||
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women | Q28191237 | ||
| Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial | Q29615226 | ||
| Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women | Q31059065 | ||
| Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate | Q33949094 | ||
| Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial | Q34208463 | ||
| Estrogen plus progestin and the risk of coronary heart disease | Q34220432 | ||
| Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial | Q34266403 | ||
| National use of postmenopausal hormone therapy: annual trends and response to recent evidence | Q34288307 | ||
| Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. | Q34497137 | ||
| Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. | Q34512916 | ||
| Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland | Q34600713 | ||
| Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. | Q34615300 | ||
| Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study | Q34941428 | ||
| Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting | Q36361043 | ||
| Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. | Q36456030 | ||
| Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society | Q36493180 | ||
| Clinical practice. Management of menopausal symptoms | Q36668701 | ||
| Estrogen plus progestin therapy and breast cancer in recently postmenopausal women | Q37163009 | ||
| A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women | Q46809765 | ||
| A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology. | Q46838190 | ||
| Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women | Q46850430 | ||
| Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study | Q46855739 | ||
| The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers | Q48378027 | ||
| A prospective population-based study of menopausal symptoms | Q48715331 | ||
| Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. | Q51079439 | ||
| The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. | Q51903432 | ||
| Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. | Q54738852 | ||
| Changes in women's attitudes towards and use of hormone therapy after HERS and WHI | Q56919164 | ||
| Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus | Q57452111 | ||
| Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women | Q61705886 | ||
| Recovery of physical function after limb injuries in independent older people living at home | Q62269372 | ||
| The normal menopause transition | Q68096956 | ||
| The prevalence of hot flash and associated variables among perimenopausal women | Q69826850 | ||
| Association of waking episodes with menopausal hot flushes | Q70733799 | ||
| Compliance with hormone replacement therapy in Thai women | Q73154076 | ||
| The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms | Q73322360 | ||
| Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years | Q73596758 | ||
| Urogenital prolapse and atrophy at menopause: a prevalence study | Q73930719 | ||
| Deterioration in quality of life following hip fracture: a prospective study | Q74060649 | ||
| A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century | Q78001948 | ||
| Mortality after osteoporotic fractures | Q79238409 | ||
| Excess mortality after hospitalisation for vertebral fracture | Q79249088 | ||
| Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study | Q79324113 | ||
| Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women | Q39312623 | ||
| Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief | Q39336361 | ||
| Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial | Q39338950 | ||
| Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials | Q39348302 | ||
| A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period | Q39359076 | ||
| Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate | Q39359084 | ||
| Hormone use and patient concerns after the findings of the Women's Health Initiative | Q39364121 | ||
| Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms | Q39392997 | ||
| Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women | Q39408485 | ||
| Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women | Q39438348 | ||
| Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial | Q39443195 | ||
| Changing use of hormone therapy among minority women since the Women's Health Initiative | Q39779124 | ||
| Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity | Q40408379 | ||
| Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens | Q41336813 | ||
| Prevalence of genitourinary and other climacteric symptoms in 61-year-old women | Q43330304 | ||
| The pathophysiology of peri- and postmenopausal bone loss. | Q43568239 | ||
| Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding | Q43625097 | ||
| Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism | Q43662494 | ||
| Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate | Q43662497 | ||
| Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens | Q43723678 | ||
| Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy | Q43854526 | ||
| Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent | Q43948658 | ||
| The effect of age and menopause on bone mineral density of the proximal femur | Q44378233 | ||
| Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results | Q44648884 | ||
| Estrogen plus progestin and colorectal cancer in postmenopausal women | Q44785535 | ||
| Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women | Q44792195 | ||
| Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study. | Q44799954 | ||
| A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group | Q44864602 | ||
| Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women | Q44913668 | ||
| The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety | Q44927297 | ||
| Estrogen plus progestin and risk of venous thrombosis | Q45092058 | ||
| Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens | Q45118185 | ||
| Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative | Q45126799 | ||
| Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. | Q45918583 | ||
| Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. | Q45918585 | ||
| Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. | Q45918586 | ||
| Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial | Q46110515 | ||
| The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention | Q46429159 | ||
| Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results | Q46484277 | ||
| Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study | Q46515026 | ||
| A randomized, placebo-controlled trial of the effects of physical exercises and estrogen therapy on health-related quality of life in postmenopausal women. | Q46542357 | ||
| Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial | Q46565016 | ||
| Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland | Q46681785 | ||
| A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study | Q46687884 | ||
| Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses | Q46718172 | ||
| Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial | Q46797366 | ||
| Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects | Q46797373 | ||
| Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women | Q46802787 | ||
| P433 | issue | 7 | |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 533-544 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms | |
| P478 | volume | 27 |
| Q38193873 | Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause |
| Q38192058 | Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy |
| Q36776727 | Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes |
| Q30353161 | Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice |
| Q28085599 | Estrogen: an emerging regulator of insulin action and mitochondrial function |
| Q37095740 | Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination |
| Q36432425 | The Dual Estrogen Receptor α Inhibitory Effects of the Tissue-Selective Estrogen Complex for Endometrial and Breast Safety |
| Q26781733 | The Recent Review of the Genitourinary Syndrome of Menopause |
| Q45348574 | The effects of conjugated estrogen, raloxifene and soy extract on collagen in rat bones |
| Q30456770 | Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model |
| Q37801227 | Tissue-Selective Agents: Selective Estrogen Receptor Modulators and the Tissue-Selective Estrogen Complex |
| Q36136356 | Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine |
Search more.